Aviso: antes de depositar, asegúrate que el documento no está ya en el repositorio. Para ello busca por el título: escribe solo la primera parte y excluye los dos puntos, guiones, etc. y la frase posterior.
Para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
(Current Topics in Medicinal Chemistry, 2016) Michalska Dziama, Patrycja; Buendia, Izaskun; Almale Del Barrio, Laura; León Martínez, Rafael
Alzheimer's disease (AD) is the most prevalent among the aging diseases known as neurodegenerative disorders. Drug design programs over the last two decades were mainly based on the cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on the outcome of the disease. The complex nature of AD has led to new approaches for drug development programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget hybrid compounds from previously known active molecules has been one of the most widely used to obtain new candidates for the future treatment of AD. Here, we summarize recent developments based on the hybridization hypothesis to obtain a potential clinical candidate for AD.